DEVELOPMENT OF FAST-DISSOLVING TABLET(FDT) CONTAINING ONDANSETRON HYDROCHLORIDE ($Onseran^{TM}$)

To improve the compliance of oral administration of drugs in cancer patients, who are unable to swallow tablets, FDT containing ondansetron HCI($Onseran^{TM}$) was developed with a low-cost manufacturing process. $Onseran^{TM}$ was prepared from ondansetron. mannitol, crospovidone. and others with a direct compression method. The disintegration time and dissolution rate of $Onseran^{TM}$ were assessed according to the USP method. The results were compared with those of the reference drug ($Zofran^{TM}$). (omitted)